Navigation Links
Advanced Targeting Systems, Inc. Announces $3 Million Award from National Cancer Institute
Date:9/23/2010

SAN DIEGO, Sept. 23 /PRNewswire/ -- Advanced Targeting Systems, the company that pioneered the targeting of specific cell types to manipulate them for the treatment of diseases and for research into the function of biological systems, has been awarded $3 million from the National Cancer Institute (NCI). Representatives from the NCI stated that the proposal was ranked #1 for funding out of a nationwide program with hundreds of applicants. Advanced Targeting Systems will use the funds to advance its patented drug, SP-SAP, over the next two years to initiate clinical trials for cancer pain.

SP-SAP is a conjugate between the pain-processing peptide Substance P and the ribosome-inactivating protein saporin. The mechanism of action of SP-SAP is well characterized, a rarity in pain therapeutics: a small number of cells that process pathological pain signals is removed, causing relief that appears to be permanent. Normal acute pain is unaffected.

The Food and Drug Administration has recommended that the first population to undergo treatment with SP-SAP is terminal cancer patients who are resistant to opioids such as morphine. Pain due to cancer is a great fear, at times greater than even the fear of death, in the progression of the disease. To make matters worse, many times this pain is unresponsive to the last-stand treatment: opioids. There is also a common fear among terminal patients that current pain treatments will leave them unable to function normally at a time when it is personally extremely important for them. In preclinical tests, a single treatment with SP-SAP alleviated pathologic pain perception without affecting other sensory signal pathways.

Advanced Targeting Systems assembled a team of experts for this project, including: Dr. Art Frankel, leading expert on the use of targeted toxins in cancer (Scott & White Cancer Research Center); Dr. Allen Burton, author of over 60 publications on cancer pain (MD Anderson Cancer Center, Pain Medicine: sees over 10,000 cancer-related pain patients each year); and Dr. Dorothy Brown, toxicology consultant who led veterinary cancer pain studies in dogs with osteosarcoma (University of Pennsylvania). All regulatory aspects of the project will be spearheaded by the professional team at Cato Research, a full-service CRO with over 20 years of experience in drug development services, including CMC, clinical and regulatory strategies, as well as clinical trial support.  

"I am gratified that the National Cancer Institute and the peer reviewers recognize the strength and quality of the 'Dream Team' of physicians, researchers and regulatory specialists that we have put together for this project," stated Dr. Douglas Lappi, Principal Investigator and President/CSO of Advanced Targeting Systems.

The BRDG-SPAN program is supported by funds provided to the NIH under the American Recovery & Reinvestment Act of 2009, a component of the Federal Stimulus Package.

For more information, contact Denise Higgins, Vice President, Advanced Targeting Systems. Visit http://www.ATSbio.com for contact information.

This press release was issued through eReleases(R).  For more information, visit eReleases Press Release Distribution at http://www.ereleases.com.


'/>"/>
SOURCE Advanced Targeting Systems, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Aeterna Zentaris Announces NIH Grant for a Phase 1/2 Study in Advanced Prostate Cancer with AEZS-108
2. Elusys Awarded Additional $40.6 Million Under Existing U.S. Government Contract to Fund Advanced Development of Anthim, a New Treatment for Anthrax
3. Advanced Life Sciences Expands Antibiotic Pipeline
4. Advanced Life Sciences CEO Acquires $2 Million of Common Stock Through Debt for Equity Exchange
5. Reportlinker Adds Bioinformatics Market - Advanced Technologies, Global Forecast and Winning Imperatives (2009 - 2014)
6. Aegera Therapeutics Reports Survival Data from the Phase 1 Portion of its Phase 1-2 Study of AEG35156 in Combination with Sorafenib in Patients with Advanced Hepatocellular Carcinoma
7. Sermo Announces New Client Center with Advanced Mining and Monitoring of Organic Physician Dialog
8. Advanced Life Sciences Announces Successful Preclinical Data Supporting Restanza Intravenous Formulation for Hospital Use
9. Advanced Phase I and Phase II Studies of Targeted Gene Delivery Confirm That Rexin-G Impacts Survival in Chemotherapy-resistant Bone and Soft Tissue Sarcoma (ASCO 2010)
10. Onyx Pharmaceuticals Initiates Phase 1 Study of Oral Proteasome Inhibitor in Advanced Solid Tumors
11. NeoStems Advanced Adult Stem Cell Technology to be Featured at Upcoming Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/3/2016)... ... May 03, 2016 , ... Flagship ... Dr. Nancy Gillett to its Board of Directors. Dr. Gillett recently retired from ... Executive Vice President and Chief Scientific Officer. A board-certified veterinary pathologist, Dr. Gillett ...
(Date:5/3/2016)...  Dr. Thomas P. McHugh , an internationally ... Woodlands, Texas , now offers SculpSure, the new ... cells in just 25-minutes, leaving a slimmer figure for ... Americans report feeling bothered by excess weight and are ... a growing industry. This innovative new approach to non-invasive ...
(Date:5/2/2016)... (PRWEB) , ... May 02, 2016 , ... ... with its clients in mind, the fresh look and added functionality give the ... “Recent years have seen a dynamic shift in agriculture – from precision farming ...
(Date:4/29/2016)... ... April 29, 2016 , ... ... medicine, is excited to announce the launch of the Proove Health Foundation ... volunteerism, and education to promote the use of personalized medicine for tackling the ...
Breaking Biology Technology:
(Date:3/11/2016)... , March 11, 2016 http://www.apimages.com ) ... Cross reference: Picture is available at AP Images ( http://www.apimages.com ) ... DERMALOG will be used to produce the new refugee identity cards. ... biometric innovations, at CeBIT in Hanover next ... from DERMALOG will be used to produce the new refugee identity ...
(Date:3/9/2016)... YORK , March 9, 2016 This ... and future states of the RNA Sequencing (RNA Seq) ... segments such as instruments, tools and reagents, data analysis, ... Analyze various segments of the RNA-Sequencing market such as ... services Identify the main factors affecting each segment and ...
(Date:3/3/2016)... MONTEREY, Calif. , March 3, 2016  FlexTech, ... in the categories of Innovation, Research & Development, Leadership ... Industry Leadership. This is the 9 th year ... select group of companies and individuals from past ... nominations based on a pre-described set of criteria, by ...
Breaking Biology News(10 mins):